Skip to content
The Uromigos cover art

All episodes

The Uromigos, 501 episodes. Page 3 of 6.

#
Title
201

Episode 343: ESMO 2024 - TiNivo-2 Trial

202

Episode 342: ESMO 2024 Preview with Silke Gillessen

203

Episode 341: Hormone Resistance in Prostate Cancer

204

Episode 340: Cancer Immunity Cycle Update

205

Episode 339: Tres Uramigas analizan lineamientos de ESMO para GU

206

Episode 338: RCC: Debulking Nephrectomy, Adjuvant Therapy Future and More

207

Episode 337: Updated NCCN Guidelines in RCC

208

Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer

209

Episode 335: Novel immune therapies for renal cancer

210

Episodio 334 en español: Tres Uramigas ASCO 2024

211

Episode 333: The Uromigos Cup - The Netherlands

212

Episode 332: The Uromigos Cup - Germany's Entry

213

Episode 331: AUA 2024 NMIBC Highlights

214

Episode 330: ASCO 2024 Highlights

215

Episode 329: Japan in the Uromigos Cup qualifying round

216

Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies

217

Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates

218

Episode 326 ASCO24: KIM-1 in Renal Cancer

219

Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer

220

Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC

221

Episode 323 ASCO24: TDXD in Bladder Cancer

222

Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC)

223

Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original?

224

Episode 320: Team Canada's entry for the Uromigos Cup

225

Episode 319: ASCO 2024: A Preview of GU Data

226

Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases

227

Episode 317: AUA 2024 Preview with the AUA Secretary

228

Episode 316: APCCC 2024 Summary with Silke Gillessen

229

Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer

230

Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer

231

Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease

232

Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer

233

Episode 311: The Uromigos Paper of the Month - The POUT Trial

234

Episode 310: Dosing and duration of drugs from a cost perspective

235

Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer

236

Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy

237

Episode 307: Bladder-Sparing Approaches Part 2

238

Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC

239

Episode 305: FDA and Oncology Clinical Trials

240

Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC

241

Episode 303: Community GU Oncology

242

Episode 302: Part 2- Adjuvant Therapy in solid tumors

243

Episode 301: Cancer research from a global perspective.

244

Episode 300: Adjuvant PD1 Therapy in Solid Tumours

245

Episode 299: Androgen receptor ligand-directed degrader BMS-986365

246

Episode 298: ASCO GU 2024 Highlights

247

Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath

248

Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan

249

Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer

250

Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer

251

Episode 293: ASCO GU 2024: BRCAaway and CONTACT2

252

Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer

E
253

Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer

254

Episode 290: ASCO GU 2024 Preview

255

Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine

256

Episode 288: APCCC #3: Controversies around Radiotherapy

257

Episode 287 APCCC: Early Discontinuation of Therapy in HSPC

258

Episode 286: APCCC Prostate Cancer Meeting Overview

259

Episode 285: Holiday Special: Renal Cancer in 2023

260

Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023

261

Episode 283: Holiday Special: Prostate Cancer in 2023

262

Episode 282: Holiday Special: Bladder Cancer in 2023

263

Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer

264

Episode 280: IKCS 2023 Overview

265

An apology

266

Episode 279: Management of IO-resistant RCC at #UromigosLive 2023

267

Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023

268

Episode 277: NMIBC Discussion at #UromigosLive 2023

269

Episode 276: ESMO 2023 Highlights

270

Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville

271

Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise

272

Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC

273

Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer

274

Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer

275

Episode 270: ESMO 2023 - Belzutifan in renal cancer

276

Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC

277

Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

278

Episode 267: ESMO preview - things to look out for at the meeting

279

Episode 266: Radiotherapy for prostate cancer

280

Episode 265: Brachytherapy with Jeff Michalski

281

Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial

282

Episode 263: Toni Choueiri and papillary renal cancer

283

Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.

284

Episode 261: part 2 ctDNA in bladder cancer

285

Episode 260: Celeste Simon: how to make a career in translation science work.

286

Episode 259: Cystectomy for bladder cancer

287

Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1

288

Episode 257: Chana Weinstock from the FDA

289

Episode 256: ctDNA in urothelial studies.

290

Episode 255: How to get an academic paper accepted

291

Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges

292

Episode 253: Patients' perspectives on adjuvant and 1st line RCC

293

Episode 252: Talazoparib and its FDA approval in CRPC

294

Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion

295

Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1

296

Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer

297

Episode 248: ASCO23 GU highlights

298

Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC

299

Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer

300

Episode 244: ASCO 2023 PEACE-1 in CRPC